USANA Health Sciences Inc. - 10-Q Summary (Q3 2025)
Business Context and Reporting Period
This report covers the quarterly period ended September 27, 2025. USANA Health Sciences, Inc. operates as a global nutrition and wellness company with two primary reportable segments: Direct Selling (traditional business) and Hiya Direct-to-Consumer (acquired in late 2024). The company reported a net loss for the quarter, contrasting with profitability in the prior year, driven by a significant increase in the effective tax rate and operational headwinds in the direct selling segment.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Net Sales | $213.7 million | $200.2 million | $699.1 million | $640.9 million |
| Gross Profit Margin | 77.2% | 80.4% | 78.3% | 80.9% |
| Operating Income | $1.2 million | $15.6 million | $33.6 million | $58.1 million |
| Net Earnings (Loss) Attributable to USANA | $(6.5) million | $10.6 million | $12.5 million | $37.6 million |
| Diluted EPS | $(0.36) | $0.56 | $0.67 | $1.96 |
| Cash and Equivalents | $145.3 million | $181.8 million (Dec 2024) | N/A | |
| Operating Cash Flow (9M) | $25.7 million | $55.2 million | N/A | |
| Debt (Line of Credit) | $0 | $23.0 million (Dec 2024) | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated net sales increased 6.7% QoQ and 9.1% YTD, primarily driven by the inclusion of Hiya ($30.8M in Q3). However, the core Direct Selling segment declined 11.4% QoQ and 7.9% YTD on a constant currency basis.
- Profitability Decline: Operating income dropped significantly due to higher Selling, General, and Administrative (SG&A) expenses (up 960 bps QoQ) and lower operating margins in the Direct Selling segment.
- Tax Impact: The effective tax rate surged to 65.0% YTD (from 43.0% in 2024). Lower pre-tax earnings combined with a concentration of expenses in the U.S. resulted in an unexpected $7.6 million tax adjustment in Q3.
- Customer Base: Active Direct Selling customers decreased 14.2% year-over-year to 388,000. Hiya reported 193,400 active monthly subscribers.
- Liquidity: The company paid down its $23 million line of credit balance to zero. Cash reserves decreased by $36.4 million over the nine-month period due to operating cash flow reduction, investing activities, and $27.5 million in share repurchases.
Outlook, Risks, and Unusual Items
- Compensation Plan Transition: The rollout of an enhanced Brand Partner compensation plan in Q3 resulted in softer-than-expected productivity and higher incentive accruals. Management expects to focus on training and education in Q4 to leverage the new plan.
- Cost Realignment: In Q4 2025, the company initiated a global cost realignment process, expecting a one-time charge of approximately $4.7 million.
- Segment Performance: The Hiya segment contributed to revenue growth but diluted overall gross margins (Hiya gross margin ~64% vs. Direct Selling ~79%).
- Risks: Key risks include dependence on the direct selling model, regulatory challenges in China (where 46% of sales originate), foreign currency volatility, and the ability to integrate acquired businesses effectively.
Investor Verification Checklist
- Tax Rate Sustainability: Verify if the 65% effective tax rate is a one-time anomaly or indicative of a new structural reality for the company.
- Direct Selling Recovery: Monitor Q4 active customer counts and sales per customer to assess if the compensation plan transition has stabilized.
- Hiya Integration: Review future guidance on Hiya's path to profitability and its impact on consolidated margins.
- Cash Flow vs. Repurchases: Assess the impact of the $27.5M share repurchase program on liquidity given the decline in operating cash flow.
- China Exposure: Evaluate the impact of the 13.6% decline in Greater China active customers on future revenue projections.